Abzena has announced upgrades to its chemistry GMP suites.
The Bristol PA site manufacturing facility upgrades allow Abzena’s ADC client projects to progress from discovery to commercial without technology transfer.
The Bristol site enhancements include two new GMP suites, one for small molecules, including high potency up to 100L scale, and one for conjugation, as well as other GMP facility upgrades.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“Customer demand for our high quality, integrated services has increased 93% since 2019. This has driven our decision to invest in our capacity for commercial GMP capacity for ADCs. We are delighted to augment our market-leading discovery, design and development capability and add to our outstanding scientific team,” Jonathan Goldman, CEO of Abzena said.